Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay

Vedolizumab (VDZ) is an anti-α(4)β(7) integrin monoclonal antibody approved for inflammatory bowel disease treatment. VDZ serum and antidrug antibody (ADA) concentrations may be used for treatment optimization. In this article, the results of 5 commercial assays (Grifols, Immundiagnostik, Progenika,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vande Casteele, Niels, Yang, Lili, Dobler, Iwona, Agboton, Christian, McRorie Osborn, Teresa, Suri, Ajit, Lindner, Dirk, Smithson, Glennda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013162/
https://www.ncbi.nlm.nih.gov/pubmed/36788448
http://dx.doi.org/10.1097/FTD.0000000000001068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013162/
https://www.ncbi.nlm.nih.gov/pubmed/36788448
http://dx.doi.org/10.1097/FTD.0000000000001068

Ejemplares similares